Next Generation Immune Checkpoint Inhibitor TIM 3 Antibodies Will Be More Prominently Used As Combinational Cancer Therapy Says Kuick Research.
Next Generation Immune Checkpoint Inhibitor TIM 3 Antibodies Will Be More Prominently Used As Combinational Cancer Therapy Says Kuick Research
TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028 Report Highlights:
- Insight on Emerging TIM3 Inhibitors in Development As Monotherapy & combination Therapy
- Future Market Opportunity Insight From First Drug Approval: 2024 - 2028
- Insight On TIM3 Inhibitors Drug In clinical Trials: > 15 Drugs
- TIM3 Inhibitors Drug In Clinical Trials Insight By Country, Company, Indication
- Comprehensive Clinical Insight On Biomarker Identified During Clinical Trials
Download Report:
For decades, the hallmark of medical treatment of cancer is conventional therapies including surgery, chemotherapy and radiation. The conventional cancer therapies have shown to significantly improve the survival outcomes in patients but are associated with side effects which limit their widespread use. The advancement in the field of science has led to better understanding about the progression of disease and identification of potential therapeutic targets for the drug development. This has led to development of several targeted therapies which work by targeting specific genes or proteins which are involved in proliferation and growth of cancer cell.
Amid all targeted therapies, immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 have emerged as potential drug class in the management of cancer. Despite the impressive impact of CTLA-4 and PD-1/PD-L1 inhibitors, a large proportion of patients with many tumor types failed to respond and some develop drug resistance. Consequently, the focus has shifted to targeting alternative inhibitory receptors and suppressive mechanisms with the tumor microenvironment.
The identification of TIM-3 in 2002 and its critical role in the progression of cancer has encouraged pharmaceutical companies to developed TIM-3 targeting antibodies for the management of solid tumor as well as hematological malignancies. Currently, no TIM-3 inhibitor has gain market authorization but several others are present in clinical pipeline suggesting promising future of the market.
Several ongoing clinical trials are evaluating the role of novel TIM-3 inhibitors as monotherapy or in combinational therapy for the management of several cancers including melanoma, head and neck cancer, acute myeloid leukemia, and solid tumors. The clinical trials are ongoing to determine the optimal combination of immunotherapeutic, not only with other immune checkpoint inhibitors, but also with several front line modalities including chemotherapy, radiation therapy, and cancer vaccines.
In 2021, Sabatolimab has received fast track designation from US FDA as well as orphan drug designation by European Commission for the management of myelodsyplastic syndromes in combination with hypomethylating agents. These designations expedite the drug development process and also incentivize the pharmaceutical companies. The drug is expected to be launch in market by 2024.
For Report Sample contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366